Current treatment for nocardia infections.

Area of Science:

• Medical Microbiology
• Infectious Diseases
• Genomics

Background:

• Nocardiosis presents a diagnostic challenge due to its diverse clinical manifestations.
• It predominantly affects individuals with compromised immune systems.
• Molecular genomic advancements facilitate the identification of novel pathogenic Nocardia species.

Purpose of the Study:

• To review the taxonomy, clinical features, diagnosis, and species identification of Nocardia.
• To assess antimicrobial susceptibility patterns and therapeutic options for nocardiosis.
• To highlight the importance of accurate diagnosis and tailored treatment strategies.

Main Methods:

• Review of existing literature on Nocardia species, clinical presentations, and diagnostic methods.
• Analysis of antimicrobial susceptibility patterns for various drug classes.
• Evaluation of traditional and novel therapeutic approaches, including monotherapy and combination treatments.

Main Results:

• Identification of numerous pathogenic Nocardia species necessitates precise identification and susceptibility testing.
• Traditional antimicrobials like sulfonamides and newer agents such as oxazolidinones show varying effectiveness.
• In vitro and experimental models indicate efficacy for novel compounds like oxazolidinones and benzothiazinones.

Conclusions:

• Clinicians must maintain a high index of suspicion for nocardiosis in immunocompromised patients.
• Accurate organism identification, susceptibility profiling, and consideration of drug adverse effects are crucial.
• Treatment for nocardiosis is variable, ranging from trimethoprim-sulfamethoxazole to combination therapies and novel antibiotics, tailored to infection site, severity, and patient comorbidities.